Evidence map›Paper›PMID 40930030›Full record

ArticleRedox biology2025

Cytoskeletal disruption-induced calcium dysregulation drives cell death in anti-IgLON5 disease.

Lisanne Korn, Júlia Csatári, Andreas Schulte-Mecklenbeck, Laura Vinnenberg, Nadine Ritter, Paul Disse, Isabel Aymanns, Jan D Lünemann, Catharina C Gross, Petra Hundehege and 5 more

Abstract read
In one paragraph

Article in Redox biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lisanne KornDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Júlia CsatáriDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Andreas Schulte-MecklenbeckDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Laura VinnenbergDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany; Department of Neurology, Medical Faculty, Heinrich-Heine University of Düsseldorf, Düsseldorf, Germany.
Nadine RitterInstitute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Paul DisseInstitute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany.
Isabel AymannsInstitute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany.
Jan D LünemannDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Catharina C GrossDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Petra HundehegeDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Guiscard SeebohmInstitute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany.
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Thilo KaehneInstitute of Experimental Internal Medicine, Otto-von-Guericke University, Magdeburg, Germany.
Matthias PawlowskiDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Stjepana KovacDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. Electronic address: Stjepana.Kovac@ukmuenster.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-IgLON5 disease is an autoimmune encephalitis with more chronic presentation including memory decline, sleep disorder, bulbar symptoms and movement disorder. Post-mortem brains of patients with anti-IgLON5 disease show neurodegeneration with tau deposition sparking interest in this 'acquired tauopathy' as a disease model for neurodegeneration, yet mechanisms of neurodegeneration remain unknown. Using a reductionist human iPSC-derived neuron-antibody model, we applied proteomics approach, electrophysiology and live cell imaging. iNeurons treated with anti-IgLON5 IgG presented with cytoskeletal disruption along with tau depositions, which correlated with endophenotypes. Accompanying calcium dysregulation was driven by impaired ER refill and mitochondrial dysfunction leading to cell death. Analogous cytoskeletal disruption is also reflected in the serum of treatment naïve patients using OLink proteomics. These findings provide insight into anti-IgLON5 disease pathology and pinpoint downstream signalling events of direct antibody-neuron interactions, which involve novel targets such as cytoskeletal disruption along with calcium dysregulation.

Indexed as

AutoantibodiesAutoimmune DiseasesCalciumCytoskeletonCell Adhesion Molecules, NeuronalCell DeathHumansInduced Pluripotent Stem CellsNeuronsProteomicsAutoantibodiesCalciumCell Adhesion Molecules, NeuronalIgLON5 protein, humanAIECalcium dysregulationCytoskeletal disruptionDisease phenotypeIgLON5

Identifiers

PMID40930030
PMCPMC12454665

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.